RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 471

    1.

    Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial.

    Fisher RI, Coltman CA Jr, Doroshow JH, Rayner AA, Hawkins MJ, Mier JW, Wiernik P, McMannis JD, Weiss GR, Margolin KA, et al.

    Ann Intern Med. 1988 Apr;108(4):518-23.PMID: 3258138 [PubMed - indexed for MEDLINE]Related articles

    2.

    A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.

    Weiss GR, Margolin KA, Aronson FR, Sznol M, Atkins MB, Dutcher JP, Gaynor ER, Boldt DH, Doroshow JH, Bar MH, et al.

    J Clin Oncol. 1992 Feb;10(2):275-81.PMID: 1732429 [PubMed - indexed for MEDLINE]Related articles

    3.

    Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.

    Bergmann L, Fenchel K, Weidmann E, Enzinger HM, Jahn B, Jonas D, Mitrou PS.

    Cancer. 1993 Sep 1;72(5):1733-42.PMID: 8348502 [PubMed - indexed for MEDLINE]Related articles

    4.

    A phase II clinical trial of adoptive immunotherapy for advanced renal cell carcinoma using mitogen-activated autologous leukocytes and continuous infusion interleukin-2.

    Wang JC, Walle A, Novogrodsky A, Suthanthiran M, Silver RT, Bander NH, Rubin AL, Stenzel KH.

    J Clin Oncol. 1989 Dec;7(12):1885-91.PMID: 2555451 [PubMed - indexed for MEDLINE]Related articles

    5.

    A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancer.

    Gambacorti-Passerini C, Hank JA, Albertini MR, Borchert AA, Moore KH, Schiller JH, Bechhofer R, Borden EC, Storer B, Sondel PM.

    J Immunother Emphasis Tumor Immunol. 1993 Jan;13(1):43-8.PMID: 8435431 [PubMed - indexed for MEDLINE]Related articles

    6.

    Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.

    Clark JW, Smith JW 2nd, Steis RG, Urba WJ, Crum E, Miller R, McKnight J, Beman J, Stevenson HC, Creekmore S, et al.

    Cancer Res. 1990 Nov 15;50(22):7343-50.PMID: 2224862 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.

    Sznol M, Clark JW, Smith JW 2nd, Steis RG, Urba WJ, Rubinstein LV, VanderMolen LA, Janik J, Sharfman WH, Fenton RG, et al.

    J Natl Cancer Inst. 1992 Jun 17;84(12):929-37.PMID: 1629914 [PubMed - indexed for MEDLINE]Related articles

    8.

    Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma.

    Thompson JA, Bianco JA, Benyunes MC, Neubauer MA, Slattery JT, Fefer A.

    Cancer Res. 1994 Jul 1;54(13):3436-41.PMID: 8012963 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen.

    Parkinson DR, Fisher RI, Rayner AA, Paietta E, Margolin KA, Weiss GR, Mier JW, Sznol M, Gaynor ER, Bar MH, et al.

    J Clin Oncol. 1990 Oct;8(10):1630-6.PMID: 2213100 [PubMed - indexed for MEDLINE]Related articles

    10.

    Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma.

    Thompson JA, Shulman KL, Benyunes MC, Lindgren CG, Collins C, Lange PH, Bush WH Jr, Benz LA, Fefer A.

    J Clin Oncol. 1992 Jun;10(6):960-8.PMID: 1588376 [PubMed - indexed for MEDLINE]Related articles

    11.

    [Usefulness and limitation of immunotherapy of metastatic renal cell carcinoma with autologous lymphokine-activated killer cells and interleukin 2]

    Nakano E, Iwasaki A, Seguchi T, Sugao H, Tada Y, Matsuda M, Sonoda T.

    Nippon Hinyokika Gakkai Zasshi. 1991 Mar;82(3):395-404. Japanese. PMID: 2072602 [PubMed - indexed for MEDLINE]Related articles

    12.

    Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study.

    Negrier S, Philip T, Stoter G, Fossa SD, Janssen S, Iacone A, Cleton FS, Eremin O, Israel L, Jasmin C, et al.

    Eur J Cancer Clin Oncol. 1989;25 Suppl 3:S21-8.PMID: 2697575 [PubMed - indexed for MEDLINE]Related articles

    13.

    A phase II clinical trial of interleukin-2 and lymphokine-activated killer cells in advanced colorectal carcinoma.

    Hawkins MJ, Atkins MB, Dutcher JP, Fisher RI, Weiss GR, Margolin KA, Rayner AA, Sznol M, Parkinson DR, Paietta E, et al.

    J Immunother Emphasis Tumor Immunol. 1994 Jan;15(1):74-8.PMID: 8110733 [PubMed - indexed for MEDLINE]Related articles

    14.

    Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells.

    Bar MH, Sznol M, Atkins MB, Ciobanu N, Micetich KC, Boldt DH, Margolin KA, Aronson FR, Rayner AA, Hawkins MJ, et al.

    J Clin Oncol. 1990 Jul;8(7):1138-47.PMID: 2358835 [PubMed - indexed for MEDLINE]Related articles

    15.

    Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma.

    Whitehead RP, Ward D, Hemingway L, Hemstreet GP 3rd, Bradley E, Konrad M.

    Cancer Res. 1990 Oct 15;50(20):6708-15.PMID: 2208137 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Phase I study of interleukin-2 combined with interferon-alpha and 5-fluorouracil in patients with metastatic renal cell cancer.

    Sella A, Kilbourn RG, Gray I, Finn L, Zukiwski AA, Ellerhorst J, Amato RJ, Logothetis CJ.

    Cancer Biother. 1994 Summer;9(2):103-11.PMID: 7812360 [PubMed - indexed for MEDLINE]Related articles

    17.

    Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results.

    Tomita Y, Katagiri A, Saito K, Imai T, Saito T, Tanikawa T, Terunuma M, Nishiyama T, Takahashi K.

    Int J Urol. 1998 Jan;5(1):16-21.PMID: 9535595 [PubMed - indexed for MEDLINE]Related articles

    18.

    Randomized study of interleukin 2 (IL-2) alone vs IL-2 plus lymphokine-activated killer cells for treatment of melanoma and renal cell cancer.

    Koretz MJ, Lawson DH, York RM, Graham SD, Murray DR, Gillespie TM, Levitt D, Sell KM.

    Arch Surg. 1991 Jul;126(7):898-903.PMID: 1854252 [PubMed - indexed for MEDLINE]Related articles

    19.

    Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.

    Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE.

    JAMA. 1994 Mar 23-30;271(12):907-13.PMID: 8120958 [PubMed - indexed for MEDLINE]Related articles

    20.

    Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.

    Boldt DH, Mills BJ, Gemlo BT, Holden H, Mier J, Paietta E, McMannis JD, Escobedo LV, Sniecinski I, Rayner AA, et al.

    Cancer Res. 1988 Aug 1;48(15):4409-16.PMID: 3260537 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity